Michael Davidson

Prof. Dr. Michael Davidson


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
MDMichael Davidson
Michael Davidson
SGSilvana Galderisi
Silvana Galderisi
MWMark Weiser
Mark Weiser
NWNomi Werbeloff
Nomi Werbeloff
WFWolfgang W. Fleischhacker
Wolfgang W. Fleischhacker
RKRené S. Kahn
René S. Kahn

31 December 2017 in Dialogues in clinical neuroscience
Verified
Journal Article
Open access
MDMichael Davidson
Michael Davidson
Despite significant progress in the study of the epidemiology and genetics of autism, the etiology and patho-physiology of this condition is far from being elucidated and no curative treatment currently exists. Although solid scientific research continues, in an attempt to find explanations and solutions, a number of nonscientific and pure myths about autism have emerged. Myths that vaccines or mercury are associated with autism have been amplified by misguided scientists; frustrated, but effective parent groups; and politicians. Preventing the protection provided by vaccination or administration of mercury-chelating agents may cause real damage to autistic individuals and to innocent bystanders who as a result may be exposed to resurgent diseases that had already been “extinguished. ” That such myths flourish is a consequence of the authority of scientific evidence obtained by scientific methodology losing ground to alternative truths and alternative science. This article presents a narrative of the origin of the myths around autism.

25 February 2022 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
MDMichael Davidson
Michael Davidson
JSJay Saoud
Jay Saoud
CSCorinne Staner
Corinne Staner
NNNadine Noel
Nadine Noel
SWSandra Werner
Sandra Werner
RLRemy Luthringer
Remy Luthringer
This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar patient population. Roluperidone 32 mg/day, roluperidone 64 mg/day, or placebo was administered for 12 weeks to 513 patients with schizophrenia with moderate to severe negative symptoms. The primary endpoint was the PANSS-derived Negative Symptom Factor Score (NSFS) and the key secondary endpoint was Personal and Social Performance scale (PSP) total score. NSFS scores were lower (improved) for roluperidone 64 mg compared to placebo and marginally missing statistical significance for the intent-to-treat (ITT) analysis data set (P ≤ .064), but reached nominal significance (P ≤ .044) for the modified-ITT (m-ITT) data set. Changes in PSP total score were statistically significantly better on roluperidone 64 mg compared to placebo for both ITT and m-ITT (P ≤ .021 and P ≤ .017, respectively). Results of this trial confirm the potential of roluperidone as a treatment of negative symptoms and improving everyday functioning in patients with schizophrenia. Study registration: Eudra-CT: 2017-003333-29; NCT03397134.

1 April 2019 in Schizophrenia Research
Verified
Journal Article
Closed access
MWMark Weiser
Mark Weiser
LLLinda Levi
Linda Levi
SBShimon Burshtein
Shimon Burshtein
RCRoxana Chiriță
Roxana Chiriță
DCDiana Cirjaliu
Diana Cirjaliu
JDJohn M. Davis
John M. Davis

17 July 2024 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
SJSydney H. James
Sydney H. James
AAAnthony O. Ahmed
Anthony O. Ahmed
PHPhilip D Harvey
Philip D Harvey
JSJay B. Saoud
Jay B. Saoud
MDMichael Davidson
Michael Davidson
GSGregory P. Strauss
Gregory P. Strauss

1 January 2023 in Schizophrenia Bulletin Open
Verified
Journal Article
Open access
PDF file
DDDavid G Daniel
David G Daniel
ACAlex S. Cohen
Alex S. Cohen
DVDawn Velligan
Dawn Velligan
PHPhillip D Harvey
Phillip D Harvey
LALarry Alphs
Larry Alphs
SMStephen R Marder
Stephen R Marder
In contrast to the validated scales for face-to-face assessment of negative symptoms, no widely accepted tools currently exist for remote monitoring of negative symptoms. Remote assessment of negative symptoms can be broadly divided into 3 categories: (1) remote administration of an existing negative-symptom scale by a clinician, in real time, using videoconference technology to communicate with the patient; (2) direct inference of negative symptoms through detection and analysis of the patient’s voice, appearance, or activity by way of the patient’s smartphone or other device; and (3) ecological momentary assessment, in which the patient self-reports their condition upon receipt of periodic prompts from a smartphone or other device during their daily routine. These modalities vary in cost, technological complexity, and applicability to the different negative-symptom domains. Each modality has unique strengths, weaknesses, and issues with validation. As a result, an optimal solution may be more likely to employ several techniques than to use a single tool. For remote assessment of negative symptoms to be adopted as primary or secondary endpoints in regulated clinical trials, appropriate psychometric standards will need to be met. Standards for substituting 1 set of measures for another, as well as what constitutes a “gold” reference standard, will need to be precisely defined and a process for defining them developed. Despite over 4 decades of progress toward this goal, significant work remains to be done before clinical trials addressing negative symptoms can utilize remotely assessed secondary or primary outcome measures.